Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCL
Public ClinicalTrials.gov record NCT04697160. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Observational Retrospective Cohort Study of Systemic Therapies for Relapsed or Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL), to Compare Outcomes to Those From Tafasitamab + Lenalidomide in the L-MIND Study
Study identification
- NCT ID
- NCT04697160
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Lead sponsor
- MorphoSys AG
- Industry
- Enrollment
- 3,573 participants
Conditions and interventions
Conditions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2020
- Primary completion
- May 6, 2021
- Completion
- May 6, 2021
- Last update posted
- Oct 19, 2021
2020 – 2021
United States locations
- U.S. sites
- 22
- U.S. states
- 16
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| MorphoSys Research Site | Scottsdale | Arizona | 85258 | — |
| MorphoSys Research Site | Clovis | California | 93611 | — |
| MorphoSys Research Site | Los Angeles | California | 90015 | — |
| MorphoSys Research Site | Orange | California | 92868 | — |
| MorphoSys Research Site | Torrance | California | 90502 | — |
| MorphoSys Research Site | Broomfield | Colorado | 80021 | — |
| MorphoSys Research Site | Chicago | Illinois | 60637 | — |
| MorphoSys Research Site | Skokie | Illinois | 60077 | — |
| MorphoSys Research Site | Indianapolis | Indiana | 46260 | — |
| MorphoSys Research Site | Wichita | Kansas | 67214 | — |
| MorphoSys Research Site | Ann Arbor | Michigan | 48109 | — |
| MorphoSys Research Site | Minneapolis | Minnesota | 55455 | — |
| MorphoSys Research Site | Rochester | Minnesota | 55905 | — |
| MorphoSys Research Site | Jackson | Mississippi | 39216 | — |
| MorphoSys Research Site | Morristown | New Jersey | 07960 | — |
| MorphoSys Research Site | New York | New York | 10029 | — |
| MorphoSys Research Site | New York | New York | 10075 | — |
| MorphoSys Research Site | Charlotte | North Carolina | 28204 | — |
| MorphoSys Research Site | Portland | Oregon | 97239 | — |
| MorphoSys Research Site | Nashville | Tennessee | 37232 | — |
| MorphoSys Research Site | Salt Lake City | Utah | 84112 | — |
| MorphoSys Research Site | Spokane | Washington | 99218 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 143 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04697160, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 19, 2021 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04697160 live on ClinicalTrials.gov.